EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual

Murray Baron iD, Mandana Nikpour, Dylan Hansen, Susanna Proudman iD, Wendy Stevens, Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group, Mianbo Wang

Arthritis Care & Research · 2025

DOI: 10.1002/acr.25467 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Arthritis Care & Research, 2025. Verfasst von Murray Baron und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jewish General Hospital, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Scleroderma, Systemic. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scleroderma Canada, Mallinckrodt Pharmaceuticals, Arthritis Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Organ damage in patients with systemic sclerosis (SSc) in individual organs such as the lungs may be prevented by receiving immunosuppressive drugs (ISs). A new measure of global organ damage, the Scleroderma Clinical Trials Consortium Damage Index (SCTC‐DI), has allowed us to investigate whether receiving ISs may reduce global organ damage accrual in patients with early SSc.

Methods

This was a retrospective study of patients with two or less years of disease duration in Canadian and Australian cohorts with SSc. Patients with either limited cutaneous SSc (lcSSc) or diffuse cutaneous SSc (dcSSc) were observed separately and divided into groups who were either ever or never exposed to ISs. The SCTC‐DI was the outcome, and inverse probability of treatment weighting (IPTW) was used to balance the study groups and to fit a marginal structural generalized estimating equation model.

Results

In the cohort with lcSSc, there were 210 patients, of whom 34% were exposed to ISs at some time. Exposure to ISs was associated with lower damage scores. In the cohort with dcSSc, there were 192 patients, of whom 76% were exposed to ISs at some time. Exposure to ISs was not associated with damage scores.

Conclusion

In this retrospective observational cohort study, using IPTW to adjust for confounders, we found a protective effect of receiving ISs on damage accrual in patients with lcSSc. We were unable to determine such an effect in patients with dcSSc, but unknown confounders may have been present, and prospective studies of patients with dcSSc receiving ISs should include the SCTC‐DI to determine the possible effect of ISs on damage accrual.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunosuppressive AgentsScleroderma, SystemicHumansRetrospective StudiesFemaleMaleMiddle AgedAdultAgedCanadaTreatment OutcomeAustraliaTime Factors

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
  • The University of Sydney and Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
  • The University of Sydney, Camperdown, New South Wales, Australia.
  • Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
  • Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

ORCID-Profile: Murray Baron, Susanna Proudman

Förderung

  • Scleroderma Canada
  • Mallinckrodt Pharmaceuticals
  • Arthritis Australia
  • CIHR
  • Scleroderma Society of Nova Scotia
  • Boehringer Ingelheim
  • Scleroderma Manitoba
  • Scleroderma Association of British Columbia

Zitieren

APA

Baron, M., Nikpour, M., Hansen, D., Proudman, S., Stevens, W., Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group, & Wang, M. (2025). Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual. Arthritis Care & Research. https://doi.org/10.1002/acr.25467

Vancouver

Baron M, Nikpour M, Hansen D, Proudman S, Stevens W, Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group, et al. Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual. Arthritis Care & Research. 2025. doi:10.1002/acr.25467

BibTeX
@article{Baron2025,
  author = {Baron, Murray and Nikpour, Mandana and Hansen, Dylan and Proudman, Susanna and Stevens, Wendy and Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group, Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group and Wang, Mianbo},
  title = {Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual},
  journal = {Arthritis Care & Research},
  year = {2025},
  doi = {10.1002/acr.25467}
}
Kostenlos starten →